Historique
Article de Périodique
Standardising monitoring data on drug-related infectious diseases among people who inject drugs in Europe - an update of the European Union Drugs Agency technical protocol, 2024 (2025)
Auteur(s) :
SPERLE, I. ;
SEYLER, T. ;
PERICOLI, F. ;
DUFFELL, E. ;
HUTCHINSON, S. ;
JAUFFRET-ROUSTIDE, M. ;
KABERG, M. ;
KIVITE-URTANE, A. ;
SEGUIN-DEVAUX, C. ;
SYPSA, V. ;
ZIMMERMANN, R.
Année
2025
Page(s) :
art. 2500007
Langue(s) :
Anglais
Refs biblio. :
21
Domaine :
Drogues illicites / Illicit drugs
Discipline :
MAL (Maladies infectieuses / Infectious diseases)
Thésaurus géographique
EUROPE
Organismes
EUDA
Thésaurus mots-clés
INFECTION
;
SURVEILLANCE EPIDEMIOLOGIQUE
;
METHODE
;
USAGER
;
INJECTION
;
PRODUIT ILLICITE
;
VIH
;
HEPATITE
;
PREVALENCE
;
MORBIDITE
;
INCIDENCE
;
FACTEUR DE RISQUE
;
INDICATEUR
;
PRISE EN CHARGE
;
DEPISTAGE
Résumé :
Drug-related infectious diseases (DRID), such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV), contribute to high morbidity and mortality among people who inject drugs (PWID). The European Union Drugs Agency (EUDA) is responsible for monitoring DRID and related behaviours for PWID in Europe. We updated the EUDA DRID technical protocol which covers all steps from planning to data analysis needed for a survey among PWID. Drug-related infectious disease-specific indicators were revised. To enable a more effective monitoring of the current epidemiological situation, we added specific core indicators, such as prevalence of viraemic HBV, HCV and HIV care cascades and harm reduction-related indicators. HIV pre-exposure prophylaxis and take-home naloxone were added as optional indicators. The process was informed by a European working group, who shared best-practice examples of (repeated) cross-sectional and cohort surveys using different methods in various settings. To reach the World Health Organization's goal of ending HIV and the viral hepatitis epidemics, comprehensive DRID monitoring among the disproportionately affected PWID population is needed. [Author's abstract]
Affiliation :
Robert Koch Institute (RKI), Berlin, Germany.
European Union Drugs Agency (EUDA), Lisbon, Portugal.
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Glasgow Caledonian University, Glasgow, Scotland.
Public Health Scotland (PHS), Edinburgh, Scotland.
Centre d'étude des mouvements sociaux (Inserm U1276/CNRS UMR 8044/EHESS), Paris, France.
Karolinska Institutet (KI), Department of Global Public Health, Stockholm, Sweden.
Institute of Public Health, Riga Stradins University, Riga, Latvia.
Luxembourg Institute of Health, Strassen, Luxembourg.
Medical School, National and Kapodistrian University of Athens, Athens, Greece.
European Union Drugs Agency (EUDA), Lisbon, Portugal.
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
Glasgow Caledonian University, Glasgow, Scotland.
Public Health Scotland (PHS), Edinburgh, Scotland.
Centre d'étude des mouvements sociaux (Inserm U1276/CNRS UMR 8044/EHESS), Paris, France.
Karolinska Institutet (KI), Department of Global Public Health, Stockholm, Sweden.
Institute of Public Health, Riga Stradins University, Riga, Latvia.
Luxembourg Institute of Health, Strassen, Luxembourg.
Medical School, National and Kapodistrian University of Athens, Athens, Greece.